65,437 trials
Neuropathic Pain
Primary: Change From Baseline to Days 24-28 in Numerical Rating Scale (NRS) Average Pain Score. — -1.35; -1.50; -1.61 Scores on a scale
Renal Insufficiency
Primary: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) — 305315.22; 435500.38; 658413.69 pg*hr/mL
Skin Irritation
Primary: Area of Erythema and Elevated Responses of Skin to Product — 91; 68; 33; 42 participants
Breast Cancer
Primary: Plasma Sex Hormone Levels
Cancer · Carcinoma · Castrate-Resistant Prostate Cancer
Primary: Overall Survival Through Month 24 — 174; 184 Participants
Contraception
Primary: Number of Participants Choosing Each Hormonal Contraceptive Method Before and After Counseling — 1207; 1199; 60; 131 Participants — p=0.705
Cataract
Primary: Monocular Uncorrected Distance Visual Acuity (Monocular UCDVA) at Month 3 — 0.089; 0.225 logMAR
Tobacco Dependence
Primary: A Difference Score for the Log Value of K. — -1.2215; -1.6742 log transformed values of K
Obesity · Insulin Resistance · Impaired Glucose Tolerance
Primary: Leg Blood Flow Response to Insulin — 0.24; 0.26; 0.353; 0.046 Liters/minute
Cancer
Primary: Mean (SD) Maximum Observed Concentration (Cmax) of Eribulin — 207; 106 ng*mL
Optic Neuritis
Primary: Retinal Nerve Fiber Layer Thickness at Baseline and Month 6 — 128.1; 130.5; 89.5; 88.0 µm
Retinal Disease
Primary: Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at Two Years Compared to Baseline — 0 ETDRS letters
Autoimmune Diseases · Renal Disorders · Hematologic Disorders
Primary: Percent Efficiency of Plasma Removal During the Therapeutic Plasma Exchange Procedure — 81.9; 75.2 percentage of plasma removal efficiency — p=<0.001
Severe Sepsis · Septic Shock
Primary: Ventilator-free Days (VFDs) Over 28 Days — 21.0; 17.5; 19.0 Days
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 — -0.61; -0.08 percent of HbA1c in blood — p=0.010